Avalanche Biotechnologies, a early-stage biotech developing gene therapies for wet AMD and other ophthalmic diseases, announced terms for its IPO on Monday. The Menlo Park, CA-based company plans to raise $76 million by offering 5.4 million shares at a price range of $13 to $15. At the midpoint of the proposed range. Avalanche would command a fully diluted market value of $353 million.
Avalanche Biotechnologies, which was founded in 2006, plans to list on the NASDAQ under the symbol AAVL. Jefferies & Co., Cowen & Company, Piper Jaffray are the joint bookrunners on the deal.
